SCHEMBL16645228

SCHEMBL16645228

O=C(COc1cccnc1)N1CCc2cc(NS(=O)(=O)CCC(F)(F)F)ccc2C1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.75
L3MBTL1 Q9Y468 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
ACVR1 Q04771 1/20 0.40
ALDH1A1 P00352 3/20 0.40
FLT3 P36888 5/20 0.40
CHEK1 O14757 4/20 0.40
MAPT P10636 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
GAA P10253 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
BRS3 P32247 1/20 0.39
KIT P10721 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16634691 0.88 NAMPT (0.77) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL29478194 0.86 NAMPT (1.00) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634738 0.86 NAMPT (1.00) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634818 0.85 NAMPT (0.76) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634834 0.85 NAMPT (0.75) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634908 0.82 NAMPT (0.70) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634780 0.81 NAMPT (0.67) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634820 0.80 NAMPT (0.70) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16645229 0.80 NAMPT (0.67) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1
SCHEMBL16634756 0.80 NAMPT (0.67) NAMPTL3MBTL1PTGDR2ACVR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT NAMPT 1/4885L3MBTL1 2527/4885PTGDR2 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.